Nigeria

### Tuberculosis profile

**Population 2018**: 196 million

<table>
<thead>
<tr>
<th>Estimates of TB burden, 2018</th>
<th>Number (thousands)</th>
<th>Rate (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total TB incidence</td>
<td>429 (280–609)</td>
<td>219 (143–311)</td>
</tr>
<tr>
<td>HIV-positive TB incidence</td>
<td>53 (34–75)</td>
<td>27 (17–38)</td>
</tr>
<tr>
<td>MDR/RR-TB incidence*</td>
<td>21 (13–32)</td>
<td>11 (6.4–16)</td>
</tr>
<tr>
<td>HIV-negative TB mortality</td>
<td>130 (73–190)</td>
<td>64 (37–98)</td>
</tr>
<tr>
<td>HIV-positive TB mortality</td>
<td>32 (20–47)</td>
<td>16 (10–24)</td>
</tr>
</tbody>
</table>

### Estimated proportion of TB cases with MDR/RR-TB, 2018

- **New cases**: 4.3% (3.2–5.5)
- **Previously treated cases**: 15% (11–19)

### TB case notifications, 2018

- **Total new and relapse**: 103 921
  - % tested with rapid diagnostics at time of diagnosis: 54%
  - % with known HIV status: 100%
  - % pulmonary: 96%
  - % bacteriologically confirmed**: 77%
  - % children aged 0-14 years: 8%
  - % women: 34%
  - % men: 58%
- **Total cases notified**: 106 533

### Universal health coverage and social protection

- **TB treatment coverage (notified/estimated incidence), 2018**: 24% (17–37)
- **TB patients facing catastrophic total costs, 2017**: 71% (68–73)
- **TB case fatality ratio (estimated mortality/estimated incidence), 2018**: 38% (19–59)

### TB/HIV care in new and relapse TB patients, 2018

- **Number**:
  - % with known HIV status who are HIV-positive: 12 700 (12%)
  - on antiretroviral therapy: 11 032 (87%)

### Drug-resistant TB care, 2018

- % of bacteriologically confirmed TB cases tested for rifampicin resistance**: 65%
  - **New cases**: 88%
  - **Previously treated cases**: 88%

### Laboratory-confirmed cases*

- MDR/RR-TB: 2 275, XDR-TB: 31

### Patients started on treatment**

- MDR/RR-TB: 1 895, XDR-TB: 14
  - MDR/RR-TB cases tested for resistance to second-line drugs: 1 895

### Treatment success rate and cohort size

- **New and relapse cases registered in 2017**: 86% 101 734
- **Previously treated cases, excluding relapse, registered in 2017**: 82% 2 781
- **HIV-positive TB cases registered in 2017**: 76% 13 851
- **MDR/RR-TB cases started on second-line treatment in 2016**: 77% 1 251
- **XDR-TB cases started on second-line treatment in 2016**: 77% 1 251

### TB preventive treatment, 2018

- % of HIV-positive people (newly enrolled in care) on preventive treatment: 62%
- % of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment: 19% (17–21)

### TB financing, 2019

- **National TB budget (US$ millions)**: 278
  - Funding source: 8% domestic, 32% international, 60% unfunded

---

- **Ranges represent uncertainty intervals**
- **MDR** is TB resistant to rifampicin and isoniazid; **RR** is TB resistant to rifampicin
- **** Calculated for pulmonary cases only
- **Includes cases with unknown previous TB treatment history**
- **Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed**